SERIAL NO.: 09/545,139
FILED:—APRIL 7, 2000
RESPONSE TO FIRST OFFICE ACTION
PAGE 2



JUN 1 2 2001

TECH CENTER 1600/2900



## **CLEAN COPY OF AMENDMENTS**

## In the Claims

Please cancel claims 2, 10-11, 13, and 15-22 without prejudice or disclaimer.

Please add new Claims 23-102.

23.

(New) The method of Claim 1 wherein the eye condition is diabetic retinopathy.

(New) The method of Claim 1 wherein the eye condition is retinopathy of prematurity.

(New) The method of Claim 1 wherein the eye condition is corneal graft rejection.

(New) The method of Claim 1 wherein the eye condition is neovascular glaucoma.

(New) The method of Claim 1 wherein the eye condition is retrolental fibroplasias.

(New) The method of Claim 1 wherein the eye condition is epidemic keratoconjunctivitis.

(New) The method of Claim 1 wherein the eye condition is Vitamin A deficiency.

(New) The method of Claim 1 wherein the eye condition is contact lens overwear.

(New) The method of Claim 1 wherein the eye condition is atopic keratitis.

(New) The method of Claim 1 wherein the eye condition is superior limbic keratitis.

(New) The method of Claim 1 wherein the eye condition is pterygium keratitis sicca.

(New) The method of Claim 1 wherein the eye condition is myopia.

(New) The method of Claim 1 wherein the eye condition is Terrien's marginal degeneration.

(New) The method of Claim 1 wherein the eye condition is mariginal keratolysis.

6/06/2001 SMINASSI <del>000000</del>53 09545139

C/203 EX2.00 OP

38

A

SERIAL NO.: 09/545,139 FILED: APRIL 7, 2000

RESPONSE TO FIRST OFFICE ACTION

PAGE 3

(New) The method of Claim 1 wherein the eye condition is radial keratotomy.

(New) The method of Claim 1 wherein the eye condition is macular degeneration.

(New) The method of Claim 1 wherein the eye condition is post-laser complications.

(New) The method of Claim 1 wherein the eye condition is chronic retinal detachment.

(New) The method of Claim 1 wherein the eye condition is optic pits.

(New) The method of Claim 1 wherein the eye condition is a hyperviscosity syndrome.

(New) The method of Claim 1 wherein the eye condition is chronic uveitis

(New) The method of Claim 1 wherein the eye condition is chronic vitritis.

(New) The method of Claim 1 wherein the eye condition is ocular neovascular disease.

(New) The method of Claim 1 wherein the eye condition is age-related macular

degeneration.

(New) The method of Claim 1 wherein the eye condition is presumed ocular

histoplasmosis.

(New) The method of Claim 1 wherein the eye condition is an infection causing retinitis

or choroiditis.

(New) The method of Claim 1 wherein the eye condition is proliferative

vitreoretinopathy.

(New) The method of Claim 1 wherein the eye condition is scleritis.

(New) The method of Claim 1 wherein the eye condition is Eales' disease.

(New) The method of Claim 1 wherein the eye condition is Best's disease.

(New) The method of Claim 1 wherein the eye condition is trachoma.

(New) The method of Claim 12 wherein the ulcerative disease is a bacterial ulcer.

(New) The method of Claim 12 wherein the ulcerative disease is a fungal ulcer.

SERIAL NO.: **09/545,139** FILED: **APRIL 7, 2000** 

RESPONSE TO FIRST OFFICE ACTION

PAGE 4

(New) The method of Claim 1/2 wherein the ulcerative disease is Mooren's ulcer.

(New) The method of Claim 12 wherein the ulcerative disease is Wegener's sarcoidosis.

(New) The method of Claim 1/2 wherein the ulcerative disease is Stevens-Johnson disease.

(New) The method of Claim 1/2 wherein the ulcerative disease is Behcet's disease.

(New) The method of Claim 12 wherein the ulcerative disease is pemphigoid.

(New) The method of Claim 12 wherein the ulcerative disease is ulceritive colitis.

(New) The method of Claim 12 wherein the amount administered is between approximately 0.1 and approximately 300 mg/kg/day.

(New) The method of Claim 6½ wherein the amount administered is between approximately 0.5 and approximately 50 mg/kg/day.

(New) The method of Claim 68 wherein the amount administered is between approximately 1 and approximately 10 mg/kg/day.

(New) The method of Claim 1/2 wherein the compound is administered in the form of a tablet or capsule.

(New) The method of Claim 12 wherein the compound is administered in the form of a lozenge, a cachet, a solution, a suspension, an emulsion, a powder, an aerosol, a suppository, a spray, a pastille, an ointment, a cream, a paste, a foam, a gel, a tamport, or a pessary.

(New) The method of Claim 1/2 wherein the administration is oral, parenteral, transdermal, or topical.

(New) The method of Claim 1/2 wherein the administration is sublingual, buccal, rectal, vaginal, or nasal.

(New) The method of Claim 1/4 wherein the skin condition is acne.

A

57

SERIAL NO.: 09/545,139 FILED: APRIL 7, 2000

RESPONSE TO FIRST OFFICE ACTION

PAGE 5

(New) The method of Claim 14 wherein the skin condition is rosacea.

(New) The method of Claim 14 wherein the skin condition is a chemical burn.

(New) The method of Claim 14 wherein the skin condition is psoriasis.

(New) The method of Claim Wherein the amount administered is between approximately 0.1 and approximately 300 mg/kg/day.

wherein the amount administered is between (New) The method of Claim approximately 0.5 and approximately 50 mg/kg/day.

(New) The method of Claim 74 wherein the amount administered is between approximately 1 and approximately 10 mg/kg/day.

(New) The method of Claim 1/4 wherein the compound is administered in the form of a tablet or capsule.

(New) The method of Claim 14 wherein the compound is administered in the form of a lozenge, a cachet, a solution, a suspension, an emulsion, a powder, an aerosol, a suppository, a spray, a pastille, an ointment, a cream, a paste, a foam, a gel, a tamport, or a pessary.

(New) The method of Claim 1/4 wherein the administration is oral, parenteral, transdermal, or topical.

(New) The method of Claim 1/4 wherein the administration is sublingual, buccal, rectal, vaginal, or nasal.

A method for inhibiting undesired angiogenesis in a human or animal (New) wherein the angiogenesis is associated with a condition selected from the group consisting of trauma, sjogren's syndrome, phylectenulosis, sarcoid, pseudoxanthoma elasticum, Stargardt's disease, Paget's disease, Lyme's disease, par planitis, pyogenic granulomas, lipid degeneration, Crohn's disease, chronic inflammation, acoustic neuroma, and abnormal proliferation of fibrovascular or fibrous tissue comprising administering to the human or animal an angiogenesis inhibiting amount of EM-138,




SERIAL NO.: **09/545,139** FILED: **APRIL 7, 2000** 

RESPONSE TO FIRST OFFICE ACTION

PAGE 6







 $\varphi_i$ 

(New) The method of Claim 80 wherein the condition is trauma.

(New) The method of Claim & wherein the condition is sjogren's syndrome.

(New) The method of Claim & wherein the condition is phylectenulosis.

(New) The method of Claim wherein the condition is sarcoid.

(New) The method of Claim 80 wherein the condition is pseudoxanthoma elasticum.

(New) The method of Claim 80 wherein the condition is Stargardt's disease.

(New) The method of Claim & wherein the condition is Paget's disease.

(New) The method of Claim & wherein the condition is Lyme's disease.

(New) The method of Claim 80 wherein the condition is par planitis


(New) The method of Claim wherein the condition is pyogenic granulomas.

(New) The method of Claim 80 wherein the condition is lipid degeneration.

(New) The method of Claim wherein the condition is Crohn's disease.

(New) The method of Claim wherein the condition is chronic inflammation.

92



RESPONSE TO FIRST OFFICE ACTION

PAGE 7

82

(New) The method of Claim 86 wherein the condition is acoustic neuroma.

84

(New) The method of Claim 80 wherein the condition is abnormal proliferation of fibrovascular or fibrous tissue.

86. 26.

(New) The method of Claim 80 wherein the amount administered is between approximately 0.1 and approximately 300 mg/kg/day.

\$5 \$7.

(New) The method of Claim wherein the amount administered is between approximately 0.5 and approximately 50 mg/kg/day.

84

(New) The method of Claim 9 wherein the amount administered is between approximately 1 and approximately 10 mg/kg/day.

0 8/ U 99.

(New) The method of Claim 80 wherein the compound is administered in the form of a

tablet or capsule.

# # 100. W

(New) The method of Claim 80 wherein the compound is administered in the form of a lozenge, a cachet, a solution, a suspension, an emulsion, a powder, an aerosol, a suppository, a spray, a pastille, an ointment, a cream, a paste, a foam, a gel, a tamport, or a pessary.

87 191.

(New) The method of Claim 80 wherein the administration is oral, parenteral, transdermal, or topical.

402 1902

(New) The method of Claim 80 wherein the administration is sublingual, buccal, rectal, vaginal, or nasal.

